Calmer Co International Limited · ASX:CCO
Calmer Co International — Investor Presentation (September 2020)
19 slides from Calmer Co International's investor presentation, Sep 3, 2020
Slide 1: Fiji Kava
FijiKava | WELcome 70 Ful \ tae
Slide 2: Disclaimer
DISCLAIMER This presentation and any Materials provided (materials) have been prepared by Fiji Kava Limited (Fiji Kava) and contain general information about Fiji Kava activities. By accepting the Materials and attending the Fiji Kava presentation, you agree to be bound by the below terms and condit
Slide 3: 3,000 years ago, in the middle of the Pacific Ocean, a botanical marvel was found
3,000 YEARS AGO, IN THE MIDDLE OF THE PACIFIC OCEAN. A BOTANICAL MARVEL WAS FOUND. KAVA A HUMBLE ROOT WITH MAGICAL PROPERTIES. IT’S THE SECRET OF FIJI’S RELAXED, HAPPY CULTURE.
Slide 4: Fiji Kava [ASX:FIJ]
FIJI KAVA [ASX:FIJ] NOBLE KAVA SUPPLY CHAIN EXCELLENCE MEDICINAL KAVA HEALTH & WELLNESS GROWING AVAILABILITY OF FIJIAN NOBLE KAVA COMPANY WHICH PRODUCES NATURAL ‘NOBLE KAVA’ PRODUCTS FOR THE COMPLEMENTARY AND ALTERNATIVE INNOVATION & PRODUCT DEVELOPMENT MEDICINE MARKET PROMOTE THE MEDICINAL BENEFITS
Slide 5: Fiji Kava has again delivered continued momentum in its strategy during the quarter
FIJI KAVA HAS AGAIN DELIVERED CONTINUED MOMENTUM IN ITS STRATEGY DURING THE QUARTER $367k +57% +1,205% REVENUE PRIOR PRIOR CORRESPONDING Q4 FY20 PERIOD PERIOD
Slide 6: COVID-19 impacts limited, but opportunities taken to trim expenses
COVID-19 IMPACTS LIMITED, BUT OPPORTUNITIES TAKEN TO TRIM EXPENSES, STRENGTHEN REMOTE WORKING CAPACITY AND SUPPLY CHAIN RESILIENCE. Fiji currently free of community COVID-19 transmission, but cross Pacific flight restrictions still in place. Remote working across all business locations largely enabl
Slide 7: Growing global health issues
GROWING GLOBAL HEALTH ISSUES
Slide 8: The challenges of the global coronavirus pandemic has highlighted mental health and wellbeing challenges
THE CHALLENGES OF THE GLOBAL CORONAVIRUS PANDEMIC ANXIETY, HAS HIGHLIGHTED THE MENTAL HEALTH & WELLBEING CHALLENGES FACES BY SOCIETY
Slide 9: Supply chain excellence
SUPE Ly CHAI EXCELLENCE
Slide 10: Fiji Kava vertical integration and resilient supply chain remains a key competitive advantage
FIJI KAVA VERTICAL INTEGRATION & RESILIENT SUPPLY CHAIN REMAINS A KEY COMPETITIVE ADVANTAGE Plants at Fiji Kava's estate and out grower's farms were not impacted by COVID-19 or Tropical Cyclone Harold that passed over the Fiji group recently. Fiji Kava’s supply & freight to date have been uninterrup
Slide 11: Noble Kava
Aa ue NOBLE KAVA
Slide 12: Strong progress with availability at Coles, license agreement with BioCeuticals and China partner
STRONG PROGRESS WITH AVAILABILITY AT COLES, LICENSE AGREEMENT WITH BIOCEUTICALS AND STRONG PARTNER SECURED FOR CHINA NEW exclusive agreement signed with PuMate (Shanghai) Limited as China partner with minimum sales of $8m over initial three year term. Agreement covers branded Fiji Kava products & No
Slide 13: Innovation & Product Development
Slide 14: We continue to develop new innovative formats to provide consumers with safe natural alternatives
WE CONTINUE TO DEVELOP NEW INNOVATIVE FORMATS TO PROVIDE CONSUMERS WITH SAFE NATURAL ALTERNATIVES TO MEDICINES 'Sleep', 'Mind’ & 'Body’ innovation strategy, including: NEW Fiji Kava ‘Noble Sleep’ vegan capsules to induce sleep, relieve sleeplessness and support general health and wellbeing NEW Fiji
Slide 15: Medicinal Benefits
Slide 16: Fiji Kava continues to drive awareness of Fijian noble kava to support growth
FIJI KAVA CONTINUES TO DRIVE AWARENESS OF FIJIAN NOBLE KAVA TO SUPPORT GROWTH THROUGH MARKETING INITIATIVES NEW look packaging 'Sleep', ‘Calm’ & 'Body’ Targeted promotional & off location display activities with Coles to showcase and build the brand awareness nationally to over 6 million Australian
Slide 17: 1,205% growth in quarterly revenue versus prior corresponding period
FIJI KAVA 1,205% GROWTH IN QUARTERLY REVENUE VERSUS PRIOR CORRESPONDING PERIOD, SHOWING UNEVEN BUT STEADY REVENUE GROWTH $ REVENUE 000’s % PRODUCT MIX % MARKETS $800 100% 100% $700 90% 90% 80% 80% $600 70% 70% $500 60% 60% $400 50% 50% $300 40% 40% 30% 30% $200 20% 20% $100 10% 10% $0 0% 0% FY19 FY2
Slide 18: Fiji Kava [ASX:FIJ]
NOBLE KAVA SUPPLY FIJI KAVA [ASX:FIJ] CHAIN EXCELLENCE GROWING AVAILABILITY OF FIJIAN NOBLE KAVA WE WILL CONTINUE TO FOCUS ON OUR KEY STRATEGIC DRIVERS TO DELIVER INNOVATION & PRODUCT MEASURED AND SUSTAINABLE GROWTH DEVELOPMENT PROMOTE THE MEDICINAL BENEFITS OF NOBLE KAVA
Slide 19: Investor Roadshow (November 2019)
Investor Roadshow (November 2019)
Calmer Co International — Investor Presentation (September 2020) on 6ix